PUBLISHER: DataM Intelligence | PRODUCT CODE: 1290439
PUBLISHER: DataM Intelligence | PRODUCT CODE: 1290439
The Global Menopausal Hot Flashes Market size reached US$ 13.5 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 20.5 billion by 2030. The Global Menopausal Hot Flashes Market is exhibiting at a CAGR of 5.5% during the forecast period 2023-2030.
The menopausal hot flashes market is driven by factors such as an increasing prevalence of menopausal hot flashes, growing incidence of menopausal hot flashes, a growing aging population, increasing awareness and understanding of menopause and its associated symptoms, increasing focus on women's health, advancements in treatment options, and changing lifestyles and preferences.
There are many restraints and challenges associated with the menopausal hot flashes market, including limited treatment efficacy, side effects of menopausal hot flashes drugs, high cost of the treatment, and so on.
The increasing prevalence of menopausal hot flashes is a major factor driving the market share during the forecast period. The prevalence of menopausal hot flashes is increasing due to the aging women population, longer life expectancy, lifestyle changes like smoking, alcohol consumption, and junk food, hormonal changes, awareness and seeking treatment, and the need for effective management options and support for women during this stage of life.
The prevalence of hot flashes can vary among individuals, with some experiencing them more frequently and intensely than others. Healthcare providers and pharmaceutical companies are continuously working to develop and improve treatment options to alleviate the impact of hot flashes and enhance the quality of life for women experiencing this common menopausal symptom.
The side effects associated with menopausal hot flashes drugs are a major factor hindering the market share. Menopausal hot flashes drugs, including hormonal and non-hormonal medications, can have potential side effects. It is important to note that not all individuals will experience these side effects, and the severity and frequency of side effects can vary.
The COVID-19 pandemic has significantly impacted various aspects of healthcare, including the management and treatment of menopausal hot flashes. During the pandemic, healthcare systems have faced significant challenges, including overwhelmed hospitals, staff shortages, and the need to redirect resources to the COVID-19 response. Non-urgent and elective healthcare visits, including those related to menopausal symptom management, have been postponed or canceled in some cases, leading to delays in diagnosis and treatment.
The COVID-19 pandemic has had a significant psychological impact on individuals worldwide. Stress, anxiety, and emotional disturbances resulting from the pandemic can exacerbate menopausal symptoms, including hot flashes. Women may require additional support and resources to manage the psychological and emotional effects of the pandemic on their menopausal symptoms.
The Russia-Ukraine conflict impacted the menopausal hot flashes market in the region. The conflict can strain the healthcare infrastructure in the affected regions. Disruptions in healthcare services, damaged medical facilities, and displacement of healthcare professionals can affect the availability and accessibility of healthcare, including menopausal symptom management.
The conflict, directly and indirectly, affected the menopausal hot flashes market due to the stress, disruptive environment during the war, and so on. This may hamper the women's access to healthcare services, including diagnosis and treatment of menopausal hot flashes.
The Global Menopausal Hot Flashes Market is segmented based on product, distribution channel, end-user, and region.
hormonal products are expected to dominate the market share, accounting for 47.2% during the forecast period. Hormonal products, such as estrogen therapy, progesterone therapy, or combined estrogen-progestin therapy, have been widely used for many years to manage menopausal symptoms, including hot flashes. These products work by supplementing the declining estrogen levels in the body during menopause, which can help alleviate hot flashes and other associated symptoms.
Hormonal products are often considered the most effective treatment option for menopausal hot flashes, providing significant relief for many women. They are available in various formulations, including oral tablets, patches, creams, gels, and vaginal rings, offering flexibility based on individual needs.
North America holds the largest market share of 41.5% during the forecast period due to rising demand for menopausal hot flashes treatment. North America, which includes the United States and Canada, has a significant population of women in the menopausal age range, contributing to the demand for effective management of menopausal symptoms, including hot flashes.
The major global players in the market include: Bayer AG, Novartis AG, Pfizer Inc, Novo Nordisk Corporation, AbbVie Inc. (Allergan Plc), Hisamitsu Pharmaceutical Co. Inc., Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Noven Pharmaceuticals, and AstraZeneca.
The Global Menopausal Hot Flashes Market Report Would Provide Approximately 54 Tables, 46 Figures And 195 pages.
LIST NOT EXHAUSTIVE